Article
BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
International journal of clinical and experimental pathology - 1 Jan 2015
El Karak Fadi, Assi Tarek, Kourie Hampig Raphael, El Rassy Elie, Chebib Ralph, Ghor Maya, Tabchi Samer
Abstract excerpt
Vemurafenib has shown significant activity in V600 mutant melanoma; however the role of this agent in Lung adenocarcinoma with an activating BRAF mutation is still evolving. One of our patients had a rare activating BRAF mutation detected through tumor exome sequencing, which led to a switch from her successful therapy to Vemurafenib and ultimately tumor progression. The lack of adequate response was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.